Swiss pharmaceutical giant of its generics and biosimilars subsidiary today (5 September), prior to an expected spin-off in early October. The plan was announced in August last year and follows similar moves by , and .
Sandoz was formed in 2003 and has served as Novartis’ generic drug division since then. However, recent pricing pressures for generic drugs in the US have led the subsidiary to underperform expectations, leading to the decision in order to create .
This has left Novartis in the unenviable position of trying to convince shareholders that a company it doesn’t want to keep around is going to provide good value for them to remain invested in. The supplementary financials published today suggest that Sandoz’s revenue has fallen for the last three years, though it also estimates mid-single-digit net sales growth for 2023 and an increased profit margin in the mid-term.
In the listing prospectus, the company outlines the risks associated with investing in the business as is required by law. It is salient, however, that it notes the downward pricing trend of generics over time, particularly driven by competition from India and China. These uncertainties are part of the reason the .
Investors have clearly not been calmed by the financial disclosures, as Novartis stock has dipped nearly 2% since the announcement, continuing a month-long trend. It remains to be seen whether shareholders will approve the spin-off that would give them one Sandoz share for every five Novartis shares they hold.
However, there may be some saving graces. in Q2 of 2023 and plans to seek approval for four more high-profile medications before the end of this year. Of particular note is its biosimilar of Eylea, a drug marketed by to treat wet age-related macular degeneration (wAMD).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOur signals coverage is powered by , which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.
